PERPHENAN Film coated tablet Ref.[8267] Active ingredients: Perphenazine

Adults

4 mg perphenazine three times a day.

Dose may have to be adjusted upwards or downwards according to patient response. Total daily dose should not exceed 24mg.

Treatment should be started and dosage increased under close supervision.

Treatment should be reviewed at intervals to avoid indiscriminate or unduly prolonged use.

Elderly

One quarter or one half of the recommended adult dosage.

Perphenazine should be used with caution in the elderly, see section 4.4 for details.

Children

Perphenazine should not be given to children under the age of 14 years.

Method of administration

Oral.

Withdrawal symptoms seen on discontinuation of Perphenazine

Abrupt discontinuation should be avoided, see section 4.4 for details. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.

In patients who have overdosed, general supportive measures must be instituted.

Gastric lavage should be considered up to 2 hours after ingestion. Emetics are unlikely to be effective because perphenazine is a potent anti-emetic.

If hypotension is severe, fluid infusion may be needed. Central nervous system depression is treated conservatively.

Temperature should be monitored to detect hypothermia, and this should be treated appropriately. If convulsions occur, these should be managed by standard means.

Continuous monitoring of ECG should be instituted to detect any regularities of rhythm or QT interval for at least 48 hours.

36 months.

Do not store above 25°C.

Perphenan 4 mg: PVC aluminum foil blister pack containing 30 tablets or 1000 tablets.

Perphenan 8 mg: PVC aluminum foil blister pack containing 20 tablets, 30 or 1000 tablets.

Nor all pack sizes may be marketed.

None.